Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Main focus: Gene editing for next generation cellular therapies
Company stage: Pre-clinical
Diseases: Haematological- and solid tumours
Genome editing tool: CRISPR-Cas9 (Through Editas Medicine)
Funding stage: Private
Location: Dallas, Texas, USA
Partners: Editas Medicine
Sandhill’s proprietary technology, called BINATE™, leverages dual innate cell synergy, resulting in a highly activated, readily available, universal off-the-shelf treatment for both solid tumours and blood cancers. Through its collaboration with Editas Medicine, the company is developing next generation CRISPR-edited cellular therapies.